[ACRX] AcelRx Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.85 Change: 0.05 (1.79%)
Ext. hours: Change: 0 (0%)

chart ACRX

Refresh chart

Strongest Trends Summary For ACRX

ACRX is in the long-term down -75% below S&P in 9 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain (BTP). Its principal product candidate is Zalviso, an investigational pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. The company is also developing ARX-04, a Sufentanil Single-Dose NanoTab, which has completed Phase II clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as on the battlefield, in the emergency room, or in ambulatory care facilities. In addition, its product candidate pipeline consists of ARX-02, a Sufentanil NanoTab pain management system, which has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain (BTP);

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.04 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 154.93% Sales Growth - Q/Q-19.91% P/E-2.31
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-44.64% ROE-82.14% ROI-58.1%
Current Ratio4.26 Quick Ratio Long Term Debt/Equity0.32 Debt Ratio0.37
Gross Margin Operating Margin-763.87% Net Profit Margin-636.39% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities370 K Cash From Investing Activities-510 K Cash From Operating Activities-10.75 M Gross Profit
Net Profit-10.03 M Operating Profit-11.4 M Total Assets75.59 M Total Current Assets65.42 M
Total Current Liabilities15.36 M Total Debt25.14 M Total Liabilities34.51 M Total Revenue180 K
Technical Data
High 52 week5.5 Low 52 week1.7 Last close3.65 Last change-1.35%
RSI77.78 Average true range0.2 Beta0.78 Volume150.74 K
Simple moving average 20 days12.39% Simple moving average 50 days34.74% Simple moving average 200 days46.59%
Performance Data
Performance Week8.96% Performance Month46% Performance Quart71.76% Performance Half69.77%
Performance Year63.68% Performance Year-to-date80.25% Volatility daily3.96% Volatility weekly8.87%
Volatility monthly18.17% Volatility yearly62.94% Relative Volume149.89% Average Volume522.21 K
New High New Low

News

2019-08-30 09:49:42 | Why this biotech's new-school opioid is on hold with the FDA

2019-08-15 16:05:00 | AcelRx Pharmaceuticals Selected to Present at the 2019 Military Health System Research Symposium

2019-08-07 15:21:37 | Edited Transcript of ACRX earnings conference call or presentation 5-Aug-19 9:00pm GMT

2019-08-05 21:24:02 | AcelRx Pharmaceuticals Inc ACRX Q2 2019 Earnings Call Transcript

2019-08-05 17:35:09 | AcelRx Pharmaceuticals ACRX Reports Q2 Loss, Misses Revenue Estimates

2019-08-05 16:05:00 | AcelRx Pharmaceuticals Reports Second Quarter 2019 Financial Results

2019-08-02 10:12:00 | AcelRx to announce second quarter 2019 results and provide an update on the company's business on Monday, August 5th, 2019

2019-07-25 10:33:02 | Analysts Estimate AcelRx Pharmaceuticals ACRX to Report a Decline in Earnings: What to Look Out for

2019-07-25 07:29:11 | What's in the Cards for AcelRx ACRX This Earnings Season?

2019-07-01 14:00:00 | AcelRx added to the Russell 2000® and 3000® indexes

2019-06-28 18:53:36 | Hedge Funds Have Never Been More Bullish On AcelRx Pharmaceuticals Inc ACRX

2019-06-13 17:05:09 | Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I

2019-06-03 07:00:00 | AcelRx announces the closing of a $25 million senior secured debt facility

2019-05-17 09:00:01 | AcelRx Pharmaceuticals ACRX Upgraded to Buy: Here's Why

2019-05-09 15:21:45 | AcelRx Pharmaceuticals Inc ACRX Q1 2019 Earnings Call Transcript

2019-05-09 12:48:00 | Here's Why AcelRx Pharmaceuticals Fell as Much as 14% Today

2019-05-09 01:21:26 | Edited Transcript of ACRX earnings conference call or presentation 8-May-19 8:30pm GMT

2019-05-08 18:15:10 | AcelRx Pharmaceuticals ACRX Reports Q1 Loss, Lags Revenue Estimates

2019-05-08 17:09:40 | AcelRx Pharmaceuticals: 1Q Earnings Snapshot

2019-05-08 14:30:00 | AcelRx Pharmaceuticals, Inc. to Host Earnings Call

2019-05-07 16:48:08 | What's in the Cards for AcelRx ACRX This Earnings Season?

2019-05-01 10:33:02 | Will AcelRx Pharmaceuticals ACRX Report Negative Earnings Next Week? What You Should Know

2019-04-29 11:29:00 | 3 Stocks Peter Lynch Would Love

2019-04-25 16:05:00 | AcelRx to announce first quarter 2019 results and provide an update on the company's business on Wednesday, May 8th, 2019

2019-04-11 16:37:00 | AcelRx Pharmaceutical's pooled safety results for sufentanil sublingual tablets DSUVIA selected for presentation at 44th Annual Regional Anesthesiology & Acute Pain Medicine Meeting

2019-04-03 09:16:01 | Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

2019-03-28 09:00:01 | AcelRx Pharmaceuticals ACRX Upgraded to Buy: What Does It Mean for the Stock?

2019-03-11 16:01:00 | AcelRx Pharmaceuticals to Present at Oppenheimer & Co. Inc. 29th Annual Healthcare Conference

2019-03-08 12:03:00 | Why AcelRx Pharmaceuticals Stock Is Sinking Today

2019-03-08 10:00:03 | Here's Why Momentum Investors Will Love AcelRx Pharmaceuticals ACRX

2019-03-07 22:27:20 | Edited Transcript of ACRX earnings conference call or presentation 7-Mar-19 9:30pm GMT

2019-03-07 16:01:00 | AcelRx Pharmaceuticals Announces Commercial Launch of DSUVIA and Reports Fourth Quarter and Full Year 2018 Financial Results

2019-03-04 10:43:00 | 3 Top Small-Cap Stocks to Buy Right Now

2019-02-22 09:25:00 | AcelRx to announce fourth quarter 2018 results and provide a corporate update on Thursday, March 7th, 2019

2019-02-19 10:00:00 | Biotech Leaders to Watch This Week

2019-02-19 09:35:00 | 4 Healthcare Stocks Looking to Start Strong on Tuesday 2/19/19

2019-02-11 09:30:02 | Is AcelRx Pharmaceuticals ACRX Outperforming Other Medical Stocks This Year?

2019-01-31 07:00:00 | AcelRx Pharmaceutical's sufentanil sublingual tablet DSUVIA to be highlighted during a presentation at the Boswick Burn and Wound Symposium

2019-01-09 07:20:00 | Investor Expectations to Drive Momentum within PulteGroup, Dave & Buster's Entertainment, AcelRx Pharmaceuticals, LSC Communications, PNM Resources, Inc. Holding Co., and H&E Equipment Services — Discovering Underlying Factors of Influence

2019-01-07 08:30:00 | AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain

2018-12-31 16:08:01 | Penny Stocks to Buy Using Technical Analysis for January 2019

2018-12-27 09:23:00 | 2 Biotech Penny Stocks to Buy Right Now

2018-12-23 21:25:18 | Hedge Funds Are Crazy About AcelRx Pharmaceuticals Inc ACRX

2018-12-21 08:51:01 | Implied Volatility Surging for AcelRx Pharmaceuticals ACRX Stock Options

2018-12-18 07:00:00 | AcelRx Pharmaceuticals added to the NASDAQ Biotechnology Index NBI

2018-12-01 08:30:00 | 3 Stocks to Hold for the Next 20 Years

2018-11-29 16:35:00 | AcelRx Pharmaceuticals to Host Analyst and Investor Day on December 11

2018-11-21 09:25:00 | New Healthcare Trends Could Push Sector Stocks Higher

2018-11-14 16:05:00 | AcelRx Pharmaceuticals to Present at the 17th Annual ASRA Pain Medicine Meeting

2018-11-09 13:43:00 | Here's Why AcelRx Pharmaceuticals Lost as Much as 18.4% Today